BrainStorm Cell Therapeutics Inc. is a biotechnology company developing autologous stem cell therapies for highly debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson�s disease (PD) and Spinal Cord Injury. These diseases have limited treatment options and as such represent unmet medical needs. NurOwn is BrainStorm�s process for the propagation and differentiation of adult, autologous Mesenchymal Stem Cells (MSC) into NeuroTrophic Factor (NTF)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. NurOwn offers the hope of repairing degenerated tissues and curing the underlying pathology, rather than treating its symptoms. BrainStorm is conducting clinical trials with NurOwn in ALS patients. In February 2011, the United States Food and Drug Administration (FDA) granted Orphan Drug designation to NurOwn for the treatment of ALS.